Divergent Progress For Chinese Developers Of COVID Antivirals, Vaccines
Factors Include Demand, New Strains
Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.
You may also be interested in...
Chinese vaccine companies WestVac, Sinocelltech and Walvax/RNACure are leading domestic efforts to develop new shots targeting emerging SARS-CoV-2 subvariants.
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.